Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288910 · ClinicalTrials.gov registry record
Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 7
- Enrollment target
NCT02288910: Completed study, sponsored by Rush University Medical Center.
NCT02288910 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288910 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This project investigates the feasibility of assessing the relative blood volume of carcinomas in patients with Hepatocellular Carcinoma (HCC) and liver metastases from pancreatic or colorectal cancer compared to normal liver from DynaCT acquisitions on an interventional platform.
Primary Outcome
The accuracy of the DynaCT BV protocol as an indicator of healthy vs. liver tumor compared to the body CT perfusion study will evaluated using a receiver operating characteristic curve.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-07 |
What the finished NCT02288910 record still lists
NCT02288910 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02288910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02288910 about?
NCT02288910 is a clinical study titled "Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver". This project investigates the feasibility of assessing the relative blood volume of carcinomas in patients with Hepatocellular Carcinoma (HCC) and liver metastases from pancreatic or colorectal cancer compared to normal liver from DynaCT acquisitions on an interventional platform.
What is the current status of trial NCT02288910?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2014-11. Estimated completion is 2020-07.
Who is sponsoring clinical trial NCT02288910?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia